Associate Professor of Psychiatry @WUSTL ; Opinions are my own; Tweets are not medical advice.
Say my name: https://t.co/4CbvdgvJC8
Mar 17 • 7 tweets • 3 min read
1/ 4 years ago (3/17/2020), I first noticed symptoms of my first episode of COVID-19. About a week later, while experiencing the inflammatory phase, I thought of a possible way to prevent inflammation-related respiratory deterioration using an existing drug called fluvoxamine. 2/ I had a particular interest in fluvoxamine for a number of years prior to the pandemic, because of its Sigma1 receptor (S1R) agonist action, which can potentiate the effect of nerve growth factor and regulate the endoplasmic reticulum stress response. sciencedirect.com/science/articl…
Nov 15, 2022 • 5 tweets • 2 min read
Majority of people in this study reported continued post-COVID symptoms 2 years after acute infection. This is not surprising to me based on accounts I've heard from individuals who had their first SARS-CoV-2 infection more than 2 years ago. jamanetwork.com/journals/jaman…
Our original STOP COVID study was done during the first wave, and we did get some follow-up data on the majority of them, at a mean of 179 days (range 113-229) after enrollment in the RCT. Only 30% reported being 100% back to usual health at follow-up.
Join me on the clubhouse app for one or more of these fluvoxamine related rooms this weekend (Saturday & Sunday). clubhouse.com/event/m3zdO0gZ
Dec 17, 2021 • 4 tweets • 1 min read
Today NIH updated their COVID treatment guidelines to mention SC2 and TOGETHER Trials. They have not adjusted their stance on fluvoxamine. They still do not recommend either for or against fluvoxamine for COVID. Disappointing that they have not changed recommendation to “for”.
Nice article about the challenges of getting drugs approved for COVID. medscape.com/viewarticle/96…
Oct 7, 2021 • 4 tweets • 2 min read
Do you remember when you joined Twitter? I do! I joined 1 year ago, same day I presented STOP COVID fluvoxamine RCT results at an international meeting and made the abstract publicly available (wanted to see what people were tweeting about it). #MyTwitterAnniversary
On October 6, 2020, I presented “Fluvoxamine for prevention of clinical deterioration in early COVID-19: Results from a randomized placebo-controlled trial”At the ISIRV Therapeutics for COVID-19 conference. cpb-us-w2.wpmucdn.com/sites.wustl.ed…